943602-77-5Relevant articles and documents
Selective inhibitors of the mutant B-Raf pathway: Discovery of a potent and orally bioavailable aminoisoquinoline
Smith, Adrian L.,DeMorin, Frenel F.,Paras, Nick A.,Huang, Qi,Petkus, Jeffrey K.,Doherty, Elizabeth M.,Nixey, Thomas,Kim, Joseph L.,Whittington, Douglas A.,Epstein, Linda F.,Lee, Matthew R.,Rose, Mark J.,Babij, Carol,Fernando, Manory,Hess, Kristen,Le, Quynh,Beltran, Pedro,Carnahan, Josette
supporting information; experimental part, p. 6189 - 6192 (2010/03/24)
The discovery and optimization of a novel series of aminoisoquinolines as potent, selective, and efficacious inhibitors of the mutant B-Raf pathway is presented. The N-linked pyridylpyrimidine benzamide 2 was identified as a potent, modestly selective inhibitor of the B-Raf enzyme. Replacement of the benzamide with an aminoisoquinoline core significantly improved kinase selectivity and imparted favorable pharmacokinetic properties, leading to the identification of 1 as a potent antitumor agent in xenograft models. 2009 American Chemical Society.
NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE
-
Page/Page column 68-69, (2008/06/13)
The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have Formula (I) wherein R1 is Formula (II), (III) or (IV) and A1, A2, A3, A4, X, Z, Z', R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.